呼出气一氧化氮预测吸入糖皮质激素治疗反应:一项随机对照试验
这项双盲随机安慰剂对照试验纳入294例有非特异性呼吸道症状且支气管舒张可逆性<20%的未诊断患者,随机接受4周超细颗粒吸入糖皮质激素或安慰剂。
要点
- 基线FeNO每升高10 ppb,ICS对ACQ7的改善优于安慰剂。
- FeNO测定简便无创,可用于预测非特异性呼吸道症状患者的ICS反应。
- 常见不良事件为鼻咽炎、感染和呼吸道疾病,组间差异不大。
核心结论
- 在非特异性呼吸道症状且支气管舒张可逆性<20%的患者中,基线FeNO与ICS治疗反应存在显著交互作用。
研究设计与样本
- 双盲随机安慰剂对照试验,纳入18-80岁有咳嗽、喘息或呼吸困难且支气管舒张可逆性<20%的未诊断患者。
- 在英国和新加坡26个初级保健中心及医院招募,随机分配(1:1)接受4周超细颗粒ICS(QVAR 80 μg,每日两次,等效每日800 μg丙酸倍氯米松)或安慰剂。
- 随机化按基线FeNO分层:正常(≤25 ppb)、中间(>25且<40 ppb)、高(≥40 ppb)。
- 主要终点为ACQ7平均评分变化,主要和次要分析在符合方案集进行。
- 共随机分配294例(ICS组148例,安慰剂组146例),排除方案违背后分析214例(ICS组114例,安慰剂组100例)。
主要发现
- 最常见不良事件为鼻咽炎(治疗组18例[12%] vs 安慰剂组13例[9%])、感染和侵染(25例[17%] vs 21例[14%])、呼吸、胸和纵隔疾病(13例[9%] vs 17例[12%])。
关键数值与推荐
- 基线FeNO分层界值:正常≤25 ppb,中间>25且<40 ppb,高≥40 ppb。
- 支气管舒张可逆性<20%为入组条件。
临床怎么用
- 对非特异性呼吸道症状且支气管舒张可逆性<20%的患者,可检测基线FeNO以预测ICS治疗反应。
- FeNO测定简便无创,适合临床实践辅助决策。
局限性
- 主要分析基于符合方案集,排除了未完成主要终点、不依从治疗及访视超窗的患者。
- 研究未纳入有其他气道疾病证据(如慢阻肺)的患者,结论适用人群有限。
- 随访治疗仅4周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic non-specific respiratory symptoms are difficult to manage. This trial aimed to evaluate the association between baseline fractional exhaled nitric oxide (FeNO) and the response to inhaled corticosteroids in patients with non-specific respiratory symptoms. METHODS: In this double-blind randomised placebo-controlled trial, we enrolled undiagnosed patients, aged 18-80 years, with cough, wheeze, or dyspnoea and less than 20% bronchodilator reversibility across 26 primary care centres and hospitals in the UK and Singapore. Patients were assessed for 2 weeks before being randomly assigned (1:1) to 4 weeks of treatment with extrafine inhaled corticosteroids (QVAR 80 μg, two puffs twice per day, equivalent to 800 μg per day beclomethasone dipropionate) or placebo. Randomisation was stratified by baseline FeNO measurement: normal (≤25 parts per billion [ppb]), intermediate (>25 tp <40 ppb), and high (≥40 ppb). The primary endpoint was change in Asthma Control Questionnaire (ACQ7) mean score. We used generalised linear modelling to assess FeNO as a predictor of response, estimating an interaction effect between FeNO and treatment on change in ACQ7. We did our primary and secondary analyses in the per-protocol set, which excluded patients with non-completion of the primary endpoint, non-compliance to treatment (ascertained by patient report), and study visits made outside the predefined visit windows. This study is registered on ClinicalTrials.gov, number NCT02294279. FINDINGS: Between Feb 4, 2015, and July 12, 2016, we randomly assigned 294 patients to extrafine inhaled corticosteroid treatment (n=148) or placebo (n=146). Following exclusions due to protocol violations, we analysed 214 patients (114 extrafine inhaled corticosteroids and 100 placebo). We observed a significant interaction between baseline FeNO and treatment group for every 10 ppb increase in baseline FeNO, with the change in ACQ7 greater in the extrafine inhaled corticosteroids group than in the placebo group (difference between groups 0·071, 95% CI 0·002 to 0·139; p=0·044). The most common adverse events were nasopharyngitis (18 [12%] patients in the treatment group vs 13 [9%] in the placebo group), infections and infestations (25 [17%] vs 21 [14%]), and respiratory, thoracic, and mediastinal disorders (13 [9%] vs 17 [12%]). INTERPRETATION: FeNO measurement is an easy and non-invasive tool to use in clinical practice in patients with non-specific respiratory symptoms to predict response to inhaled corticosteroids. Further research is needed to examine its role in patients with evidence of other airway diseases, such as chronic obstructive pulmonary disease. FUNDING: Sponsored by OPRI with partial funding by Circassia and study drugs provided by TEVA.
引用
- Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2017. PMID: 29108938. doi:10.1016/S2213-2600(17)30424-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。